Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer.

@article{Tormey1983EvaluationOT,
  title={Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer.},
  author={Douglass C. Tormey and Marc E. Lippman and Brenda Kay Edwards and Jim Cassidy},
  journal={Annals of internal medicine},
  year={1983},
  volume={98 2},
  pages={139-44}
}
From a group of 108 female patients with measurable and/or evaluable metastatic breast carcinoma, 52 were randomized to receive tamoxifen and 56 to receive tamoxifen and fluoxymesterone. The fluoxymesterone dose, given orally twice a day, was 7 mg/m2 body surface area. The tamoxifen dose per patient, also given orally twice a day, ranged from 2 to 100 mg/m2 body surface area. Eighty-five percent of the patients had received previous chemotherapy and 60% previous hormone therapy. The complete… CONTINUE READING